Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rofecoxib.

L J Scott1, H M Lamb

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|September 24, 1999
PubMed
Summary
This summary is machine-generated.

Rofecoxib effectively treats osteoarthritis pain and inflammation by selectively inhibiting cyclo-oxygenase-2. This COX-2 inhibitor demonstrates good tolerability and fewer gastrointestinal issues compared to traditional NSAIDs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of traumatic brain injury amongst secondary school students in England: A retrospective cohort study using electronic health records.

Injury·2026
Same author

Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Drugs·2020
Same author

Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Drugs·2020
Same author

Systematic review of interventions for the prevention and treatment of postoperative urinary retention.

BJS open·2019
Same author

Correction to: The help for people with money, employment or housing problems (HOPE) intervention: pilot randomised trial with mixed methods feasibility research.

Pilot and feasibility studies·2018
Same author

The help for people with money, employment or housing problems (HOPE) intervention: pilot randomised trial with mixed methods feasibility research.

Pilot and feasibility studies·2018
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Rheumatology
  • Pain Management

Background:

  • Cyclo-oxygenase-2 (COX-2) selective inhibitors offer a potential alternative to non-selective NSAIDs.
  • Understanding the efficacy and safety profile of rofecoxib is crucial for clinical application.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of rofecoxib in patients with osteoarthritis.
  • To compare rofecoxib's analgesic effects with other pain relievers.

Main Methods:

  • Four large double-blind randomized trials assessed rofecoxib's impact on physical functioning in osteoarthritis patients.
  • Efficacy was measured using the Western Ontario and McMasters Universities Osteoarthritis Index and global assessments.
  • Analgesic efficacy was studied in primary dysmenorrhea and post-dental surgery pain.

Related Experiment Videos

Main Results:

  • Rofecoxib (12.5 and 25 mg/day) significantly improved physical functioning in osteoarthritis patients compared to placebo.
  • Rofecoxib demonstrated comparable efficacy to diclofenac, ibuprofen, and nabumetone for osteoarthritis.
  • Rofecoxib showed similar analgesic efficacy to naproxen sodium and ibuprofen for dysmenorrhea and dental pain.
  • A significantly lower incidence of upper-gastrointestinal adverse events was observed with rofecoxib compared to non-selective NSAIDs.

Conclusions:

  • Rofecoxib is an effective treatment for osteoarthritis, providing significant improvements in physical function.
  • Rofecoxib offers comparable pain relief to other analgesics with a potentially improved gastrointestinal safety profile.